Prism Medico & Pharmacy Reports Positive Financial Results for Q4 2023.

Prism Medico & Pharmacy, a microcap healthcare services company, has recently announced its financial results for the quarter ending December 2023. The company has shown a positive performance in this quarter, with its score improving from 0 to 7 in the last 3 months.

One of the key factors contributing to this positive performance is the company's operating profit (PBDIT), which has been the highest in the last five quarters at Rs 0.20 crore. This indicates a positive trend in the near term for the company's operating profit.

Similarly, the company's profit before tax less other income (PBT) has also been the highest in the last five quarters at Rs 0.19 crore, showing a positive trend in the near term. The same can be said for the company's profit after tax (PAT), which has also been the highest in the last five quarters at Rs 0.19 crore.

Moreover, the company's earnings per share (EPS) have also been the highest in the last five quarters at Rs 0.31. This indicates an increasing profitability for the company and a higher return for its shareholders.

Based on these financial results, MarketsMOJO has given a 'Sell' call for Prism Medico's stock. However, it is important to note that this is not a recommendation and should not be considered as such. This news article is purely informative and based on factual data provided by the company. Investors are advised to do their own research and analysis before making any investment decisions.